A Scripps Research team reports the discovery of a molecule that can activate a natural immune-boosting protein called STING. The findings mark a key advance in the field of oncology, as the STING protein is known for its strong antitumor … Read more
Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.
However, recent immunotherapy use … Read more
A drug known as SP-2577 could help enable the body’s own immune system to attack ovarian cancer, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.
Published today in the scientific … Read more
According to new research published in Clinical and Translational Immunology, a new cancer vaccine is ready for human trials following its success in preclinical studies.
By Alana Hippensteele
The vaccine was recently developed by a research team based at The … Read more
In cell and mouse models, miR-181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.
By Ian Demsky
A microRNA that is normally involved in immune cell differentiation helps to initiate
The FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden–high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options.… Read more
Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020).
In the interim … Read more
By Shim Hyun-tai
Antibody-based therapeutics developer Abclon said Tuesday that it has successfully drawn final candidates for the clinical trials of the next-generation chimeric antigen receptor T (CAR-T) cell therapy for ovarian cancer.
Abclon plans to enter clinical trials in … Read more
By Brita Belli
A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates … Read more
By Gina Columbus
Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival (RFS) compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease, according to phase II results from the … Read more
Malignant ovarian cancer is insidious: Known and feared for vague and uncharacteristic symptoms that often mean the disease is discovered so late that on average only four out of six patients are still alive after five years. Researchers from Aarhus … Read more
By Jason M. Broderick
An independent panel determined that the investigational agent VB-111 (ofranergene obadenovec) met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without … Read more
By Nichole Tucker
GEN-1 immunotherapy demonstrated dose-dependent efficacy results in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) when treated in combination with the standard of care, according to results from the OVATION 2 … Read more
IMV says new results from its phase 2 trial of lead drug DPX-Survivac, designed to stimulate a T cell response in ovarian cancer, have set it on course for a registration trial.
The Canadian biotech revealed data from the 22-patient … Read more
By Sharon Worcester
REPORTING FROM THE CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM
Cancer cells operate in mutational overdrive, which allows them to blow past chemotherapy and other would-be enforcers of physiological order. Cancer’s speeding, however, may prove to be a vulnerability, say scientists from the Mayo Clinic, the Institute of Cancer Research, … Read more
By Sharon Begley
As every trauma surgeon knows, there are messy bullet wounds and there are neat ones, and the former cause incomparably more trouble. If a team of scientists in China is right, the same principle may explain why … Read more
By Kashmira Gander
Scientists have discovered a new cell in the immune system that can kill many types of cancer, which they hope could one day be used to create a “one size fits all” treatment for the disease.
In … Read more
By Nichole Tucker
Preliminary data showed that the combination of sitravatinib (MGCD516) and tislelizumab (BGB-A317) is well tolerated and may promote antitumor activity when administered to patients with platinum-resistant ovarian cancer, according to a press release from BieGene, Ltd, which … Read more
By Wayne Kuznar
The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more